{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:00:34Z","timestamp":1791968434298,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:00:00Z","timestamp":1486080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.leukres.2017.01.032","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T19:47:11Z","timestamp":1485892031000},"page":"52-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy"],"prefix":"10.1016","volume":"56","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad B.","family":"Naim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilan C.","family":"Paranagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Habr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.01.032_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.032_bib0010","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative Neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0015","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0020","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1309\/6BQ5K8LHVYAKUAF4","article-title":"The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the early prepolycythemic phase of polycythemia vera and essential thrombocythemia","volume":"130","author":"Gianelli","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1078\/0344-0338-5710013","article-title":"Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients","volume":"197","author":"Thiele","year":"2001","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.leukres.2017.01.032_bib0030","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1073\/pnas.0900453106","article-title":"Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2","volume":"106","author":"De Domenico","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2017.01.032_bib0035","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1017\/jns.2013.7","article-title":"Iron deficiency, cognition, mental health and fatigue in women of childbearing age: a systematic review","volume":"2","author":"Greig","year":"2013","journal-title":"J. Nutr. Sci."},{"key":"10.1016\/j.leukres.2017.01.032_bib0040","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jnutbio.2014.07.003","article-title":"Iron and mechanisms of emotional behavior","volume":"25","author":"Kim","year":"2014","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.leukres.2017.01.032_bib0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1423-0410.2010.01427.x","article-title":"A pilot iron substitution programme in female blood donors with iron deficiency without anaemia","volume":"100","author":"Pittori","year":"2011","journal-title":"Vox Sang."},{"key":"10.1016\/j.leukres.2017.01.032_bib0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-0033-1360223","article-title":"Treatment of iron deficiency with or without anaemia with intravenous ferric carboxymaltose in gynaecological practices: a non-interventional study","volume":"74","author":"Herfs","year":"2014","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"10.1016\/j.leukres.2017.01.032_bib0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12032-009-9180-5","article-title":"High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio","volume":"27","author":"Tobiasson","year":"2010","journal-title":"Med. Oncol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0060","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MBC.0000000000000249","article-title":"Association between venous thromboembolism and iron-deficiency anemia: a population-based study","volume":"26","author":"Hung","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.leukres.2017.01.032_bib0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.20452\/pamw.3311","article-title":"Iron deficiency: a novel risk factor of recurrence in patients after unprovoked venous thromboembolism","volume":"126","author":"Potaczek","year":"2016","journal-title":"Pol. Arch. Med. Wewn."},{"key":"10.1016\/j.leukres.2017.01.032_bib0070","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/thoraxjnl-2011-201076","article-title":"Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli\/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia","volume":"67","author":"Livesey","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.leukres.2017.01.032_bib0075","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/j.1651-2227.2010.01925.x","article-title":"Childhood stroke in Sweden I: incidence, symptoms, risk factors and short-term outcome","volume":"99","author":"Christerson","year":"2010","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.leukres.2017.01.032_bib0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.032_bib0085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.032_bib0090","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0095","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1631\/jzus.B0920217","article-title":"Decreased serum prohepcidin concentration in patients with polycythemia vera","volume":"10","author":"Kwapisz","year":"2009","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.leukres.2017.01.032_bib0100","unstructured":"JAKAFI\u00ae (ruxolitinib). Full Prescribing Information, Incyte Corporation, Wilmington, DE, USA, 2016."},{"key":"10.1016\/j.leukres.2017.01.032_bib0105","unstructured":"JAKAVI\u00ae (ruxolitinib). EU Summary of Product Characteristics, Novartis Pharmaceuticals Corporation, Basel, Switzerland, 2015."},{"key":"10.1016\/j.leukres.2017.01.032_bib0110","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.032_bib0115","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80 week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.01.032_bib0120","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ejh.12707","article-title":"Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy","volume":"97","author":"Mesa","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0125","article-title":"Ruxolitinib proves superior to best available therapy in patients with polycythemia vera (PV) and a nonpalpable spleen: results from the phase IIIb RESPONSE-2 study","volume":"101","author":"Passamonti","year":"2016","journal-title":"Haematol. (EHA Annu. Meet. Abstr.)"},{"key":"10.1016\/j.leukres.2017.01.032_bib0130","article-title":"The efficacy and safety of continued hydroxyurea therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized double-blind, double-dummy, symptom study (RELIEF)","volume":"124","author":"Mesa","year":"2014","journal-title":"Blood (ASH Annu. Meet. Abstr.)"},{"key":"10.1016\/j.leukres.2017.01.032_bib0135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.032_bib0140","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2017.01.032_bib0145","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2011-01-258467","article-title":"Hepcidin and iron regulation 10 years later","volume":"117","author":"Ganz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.032_bib0150","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0155","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2014-07-551929","article-title":"How I treat polycythemia vera","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.032_bib0160","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiatedin 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0165","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/ehm.11.63","article-title":"A new era for IFN-\u03b1 in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms","volume":"4","author":"Hasselbalch","year":"2011","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0170","first-page":"897","article-title":"Iron deficiency\u2013United States, 1999\u20132000","volume":"51","author":"Centers for Disease Control and Prevention","year":"2002","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.leukres.2017.01.032_bib0175","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.032_bib0180","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0185","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.032_bib0190","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/07315724.2001.10719054","article-title":"Dietary and supplement treatment of iron deficiency results in improvements in general health and fatigue in Australian women of childbearing age","volume":"20","author":"Patterson","year":"2001","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.leukres.2017.01.032_bib0195","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.032_bib0200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd3264","article-title":"Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond","volume":"10","author":"Quint\u00e1s-Cardama","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.leukres.2017.01.032_bib0205","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nri3863","article-title":"Iron homeostasis in host defence and inflammation","volume":"15","author":"Ganz","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2017.01.032_bib0210","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/gut.2010.228874","article-title":"Guidelines for the management of iron deficiency anaemia","volume":"60","author":"Goddard","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.leukres.2017.01.032_bib0215","series-title":"Iron Deficiency Anaemia: Assessment, Prevention, and Control, a Guide for Programme Managers","author":"World Health Organization","year":"2001"},{"key":"10.1016\/j.leukres.2017.01.032_bib0220","series-title":"Assessing the Iron Status of Populations","author":"World Health Organization","year":"2004"},{"key":"10.1016\/j.leukres.2017.01.032_bib0225","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ajcp\/74.4.461","article-title":"Serum ferritin and bone marrow biopsy iron stores. II. Correlation with low serum iron and Fe\/TIBC ratio less than 15%","volume":"74","author":"Krause","year":"1980","journal-title":"Am. J. Clin. Pathol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617300449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617300449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:12:12Z","timestamp":1749939132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617300449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":45,"alternative-id":["S0145212617300449"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.032","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}